MX2025009331A - Acidos nucleicos y usos de los mismos - Google Patents
Acidos nucleicos y usos de los mismosInfo
- Publication number
- MX2025009331A MX2025009331A MX2025009331A MX2025009331A MX2025009331A MX 2025009331 A MX2025009331 A MX 2025009331A MX 2025009331 A MX2025009331 A MX 2025009331A MX 2025009331 A MX2025009331 A MX 2025009331A MX 2025009331 A MX2025009331 A MX 2025009331A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleic acids
- sarna
- self
- disclosed
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen en este documento moléculas de ARN autoamplificantes (ARNsa) que codifican un antígeno del virus de la influenza y métodos de uso de las mismas.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363484186P | 2023-02-09 | 2023-02-09 | |
| US202363484747P | 2023-02-13 | 2023-02-13 | |
| US202463621102P | 2024-01-15 | 2024-01-15 | |
| PCT/IB2024/051087 WO2024165992A1 (en) | 2023-02-09 | 2024-02-06 | Nucleic acids and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025009331A true MX2025009331A (es) | 2025-09-02 |
Family
ID=89897995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025009331A MX2025009331A (es) | 2023-02-09 | 2025-08-08 | Acidos nucleicos y usos de los mismos |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4661903A1 (es) |
| JP (1) | JP2026514290A (es) |
| KR (1) | KR20250140103A (es) |
| CN (1) | CN120882425A (es) |
| AU (1) | AU2024218431A1 (es) |
| CO (1) | CO2025010720A2 (es) |
| IL (1) | IL322137A (es) |
| MX (1) | MX2025009331A (es) |
| PE (1) | PE20252441A1 (es) |
| WO (1) | WO2024165992A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025132839A1 (en) * | 2023-12-21 | 2025-06-26 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019321186B2 (en) * | 2018-08-17 | 2024-05-23 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| AU2021392077A1 (en) * | 2020-12-02 | 2023-07-13 | Seqirus Inc. | Multicistronic rna vaccines and uses thereof |
| US20240009296A1 (en) * | 2022-07-10 | 2024-01-11 | Pfizer Inc. | Self-amplifying rna encoding an influenza virus antigen |
-
2024
- 2024-02-06 EP EP24704258.3A patent/EP4661903A1/en active Pending
- 2024-02-06 JP JP2025545786A patent/JP2026514290A/ja not_active Withdrawn
- 2024-02-06 AU AU2024218431A patent/AU2024218431A1/en active Pending
- 2024-02-06 CN CN202480018669.5A patent/CN120882425A/zh active Pending
- 2024-02-06 IL IL322137A patent/IL322137A/en unknown
- 2024-02-06 KR KR1020257028925A patent/KR20250140103A/ko not_active Withdrawn
- 2024-02-06 PE PE2025001697A patent/PE20252441A1/es unknown
- 2024-02-06 WO PCT/IB2024/051087 patent/WO2024165992A1/en not_active Ceased
-
2025
- 2025-08-05 CO CONC2025/0010720A patent/CO2025010720A2/es unknown
- 2025-08-08 MX MX2025009331A patent/MX2025009331A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2026514290A (ja) | 2026-05-08 |
| CN120882425A (zh) | 2025-10-31 |
| PE20252441A1 (es) | 2025-10-20 |
| EP4661903A1 (en) | 2025-12-17 |
| WO2024165992A1 (en) | 2024-08-15 |
| CO2025010720A2 (es) | 2025-09-08 |
| AU2024218431A1 (en) | 2025-08-14 |
| IL322137A (en) | 2025-09-01 |
| KR20250140103A (ko) | 2025-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025000397A (es) | Arn autoamplificador que codifica un antigeno del virus de la gripe | |
| BR112022025653A2 (pt) | Vacina autoamplificante de rna sars-cov-2 | |
| GEAP202416053A (en) | Modified short interfering nucleic acid (sina) molecules and uses thereof | |
| WO2021173896A8 (en) | Materials and methods for modulating an immune response | |
| EA201201025A1 (ru) | Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них | |
| JOP20210186A1 (ar) | مستضدات البروستاتا المستحدثة واستخداماتها | |
| CR20240095A (es) | Vacunas de arn | |
| CY1125681T1 (el) | Εμβολια κατα του ιου της γριπης και χρησεις αυτων | |
| CO2021007916A2 (es) | Ácido ribonucleico (arn) que codifica para una proteína | |
| MX2022009943A (es) | Vacunas intranasales de arnm. | |
| BR112018073238A2 (pt) | vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer | |
| PH12021552176A1 (en) | Antibodies and methods for treatment of influenza a infection | |
| WO2024191860A3 (en) | Nucleic acid influenza vaccines and respiratory virus combination vaccines | |
| SA522441314B1 (ar) | لقاحات لوُرام حليمي تنفسي متكرر وطرق استخدامها | |
| CO2025010720A2 (es) | Ácidos nucleicos y usos de los mismos | |
| MX2023003934A (es) | Antigenos de consenso de filovirus, construcciones de acido nucleico y vacunas realizadas a partir de estos, y metodos para utilizarlos. | |
| BR112022012350A2 (pt) | Nucleases de spcas9 de alta fidelidade para modificação de genoma | |
| WO2022009052A3 (en) | Prostate neoantigens and their uses | |
| BR112021024409A2 (pt) | Célula mutante nocaute de mdbk irf3/irf7 e seu uso para produção de vacina | |
| MX2021002933A (es) | Nucleasa pacas9. | |
| MX2022004836A (es) | Vacunas mejoradas para la papilomatosis respiratoria recurrente y métodos para su uso. | |
| MX2018007260A (es) | Metodos y composiciones de control de insectos. | |
| MX2020007676A (es) | Antígenos t grandes y pequeños del poliomavirus de células de merkel, construcciones de ácido nucleico y vacunas fabricadas con ellos, y métodos de usar los mismos. | |
| WO2022169861A3 (en) | Gene therapy for angelman syndrome | |
| WO2021158982A3 (en) | Targeted translation of rna with crispr-cas13 to enhance protein synthesis |